AZACITIDINE KABI POWDER FOR SUSPENSION FOR INJECTION 100 MG/VIAL

Fresenius Kabi Oncology Limited (INDIA)🇸🇬 Health Sciences Authority

Approval Date: Oct 30, 2025
Approval ID: 21f66cb40055801c
Company: Fresenius Kabi Oncology Limited (INDIA)
Type: Therapeutic

Approval Details

Approval Id: 21f66cb40055801c
Drug Name: AZACITIDINE KABI POWDER FOR SUSPENSION FOR INJECTION 100 MG/VIAL
Product Name: AZACITIDINE KABI POWDER FOR SUSPENSION FOR INJECTION 100 MG/VIAL
Approval Number: SIN17378P
Approval Date: 2025-10-30
Registrant: FRESENIUS KABI (SINGAPORE) PTE LTD
Licence Holder: FRESENIUS KABI (SINGAPORE) PTE LTD
Drug Type: Therapeutic
Forensic Classification: Prescription Only
Dosage Form: INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION
Dosage: 4.2 Posology and method of administration Azacitidine treatment should be initiated and monitored under the supervision of a physician experienced in the use of chemotherapeutic agents. Patients should be premedicated with anti-emetics for nausea and vomiting. Posology The recommended starting dose for the first treatment cycle, for all patients regardless of baseline haematology laboratory values, is 75 mg/m2 of body surface area, injected subcutaneously, daily for 7 days, followed by a rest period of 21 days (28-day treatment cycle). It is recommended that patients be treated for a minimum of 6 cycles. Treatment should be continued for as long as the patient continues to benefit or until disease progression. Patients should be monitored for haematologic response/toxicity and renal toxicities (see section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information); a delay in starting the next cycle or a dose reduction as described below may be necessary. Azacitidine should not be used interchangeably with oral azacitidine. Due to differences in the exposure, the dose and schedule recommendations for oral azacitidine are different from those for injectable azacitidine. Healthcare professionals are recommended to verify the name of the medicinal product, dose and administration route. Laboratory tests Liver function tests, serum creatinine and serum bicarbonate should be determined prior to initiation of therapy and prior to each treatment cycle. Complete blood counts should be performed prior to initiation of therapy and as needed to monitor response and toxicity, but at a minimum, prior to each treatment cycle. Dose adjustment due to haematological toxicity Haematological toxicity is defined as the lowest count reached (nadir) in a given cycle if platelets ≤ 50.0 × 109/L and/or absolute neutrophil count (ANC) ≤ 1 × 109/L. Recovery is defined as an increase of cell line(s) where haematological toxicity was observed of at least half of the absolute difference of nadir and the baseline count plus the nadir count (i.e. blood count at recovery ≥ nadir count + (0.5 × [|baseline count - nadir count|]). Patients without reduced baseline blood counts (i.e. white blood cells (WBC) ≥ 3.0 x 109/L and ANC ≥ 1.5 x 109/L, and platelets ≥ 75.0 x 109/L) prior to the first treatment If haematological toxicity is observed following azacitidine treatment, the next cycle of the therapy should be delayed until the platelet count and the ANC have recovered. If recovery is achieved within 14 days, no dose adjustment is necessary. However, if recovery has not been achieved within 14 days, the dose should be reduced according to the following table. Following dose modifications, the cycle duration should return to 28 days. <img src="/TGIF/AzacitidineKabi-Table1.png" alt="Azacitidine Kabi Dosage Table 1" /> Patients with reduced baseline blood counts (i.e. WBC < 3.0 x 109/L or ANC < 1.5 x 109/L or platelets < 75.0 x 109/L) prior to the first treatment Following azacitidine treatment, if the decrease in WBC or ANC or platelets from that prior to treatment is ≤ 50%, or greater than 50% but with an improvement in any cell line differentiation, the next cycle should not be delayed and no dose adjustment made. If the decrease in WBC or ANC or platelets is greater than 50% from that prior to treatment, with no improvement in cell line differentiation, the next cycle of azacitidine therapy should be delayed until the platelet count and the ANC have recovered. If recovery is achieved within 14 days, no dose adjustment is necessary. However, if recovery has not been achieved within 14 days, bone marrow cellularity should be determined. If the bone marrow cellularity is > 50%, no dose adjustments should be made. If bone marrow cellularity is ≤ 50%, treatment should be delayed and the dose reduced according to the following table: <img src="/TGIF/AzacitidineKabi-Table2.png" alt="Azacitidine Kabi Dosage Table 2" /> Following dose modifications, the next cycle duration should return to 28 days. Special populations Elderly patients No specific dose adjustments are recommended for the elderly. Because elderly patients are more likely to have decreased renal function, it may be useful to monitor renal function. Patients with renal impairment Azacitidine can be administered to patients with renal impairment without initial dose adjustment (see section 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). If unexplained reductions in serum bicarbonate levels to less than 20 mmol/L occur, the dose should be reduced by 50% on the next cycle. If unexplained elevations in serum creatinine or blood urea nitrogen (BUN) to ≥ 2-fold above baseline values and above upper limit of normal (ULN) occur, the next cycle should be delayed until values return to normal or baseline and the dose should be reduced by 50% on the next treatment cycle (see section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Patients with hepatic impairment No formal studies have been conducted in patients with hepatic impairment (see section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Patients with severe hepatic organ impairment should be carefully monitored for adverse events. No specific modification to the starting dose is recommended for patients with hepatic impairment prior to starting treatment; subsequent dose modifications should be based on haematology laboratory values. Azacitidine is contraindicated in patients with advanced malignant hepatic tumours (see sections 4.3 and 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Paediatric population The safety and efficacy of azacitidine in children aged 0–17 years have not yet been established. No data are available. Method of administration Reconstituted Azacitidine Kabi should be injected subcutaneously into the upper arm, thigh or abdomen. Injection sites should be rotated. New injections should be given at least 2.5 cm from the previous site and never into areas where the site is tender, bruised, red, or hardened. After reconstitution, the suspension should not be filtered. For instructions on reconstitution of the medicinal product before administration, see section 6.6 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.
Route Of Administration: SUBCUTANEOUS
Indication Info: 4.1 Therapeutic indications Azacitidine Kabi is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with: <ul> <li>Intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),</li> <li>Chronic myelomonocytic leukaemia (CMML) with 10–29% marrow blasts without myeloproliferative disorder,</li> <li>Acute myeloid leukaemia (AML) with 20–30% blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification.</li> </ul> Azacitidine Kabi is indicated for the treatment of adult patients aged 65 years or older who are not eligible for HSCT with AML with >30% marrow blasts according to the WHO classification.
Contraindications: 4.3 Contraindications Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information. Advanced malignant hepatic tumours (see section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Breast-feeding (see section 4.6 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

Oct 30, 2025

Approval ID

21f66cb40055801c

Type

Therapeutic

Back to HSA Approvals